Sarilumab is an interleukin-6 receptor antagonist indicated, in Canada, for rheumatoid arthritis and has been identified as a potential option for treating COVID-19. Two published studies were identified in the CADTH Horizon Scan that evaluated the efficacy and safety of sarilumab for the treatment of COVID-19.

Link to Report

CADTH Emerging Health Technology for COVID-19: Sarilumab

Provide Feedback

Was this site helpful?

If you couldn’t find what you are looking for, please submit a request.